179 related articles for article (PubMed ID: 21874010)
1. The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas.
Lee D; Do IG; Choi K; Sung CO; Jang KT; Choi D; Heo JS; Choi SH; Kim J; Park JY; Cha HJ; Joh JW; Choi KY; Kim DS
Mod Pathol; 2012 Jan; 25(1):131-9. PubMed ID: 21874010
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma.
Wang Z; Zheng T; Wu Q; Wang J; Wu C; Wang J
Neoplasma; 2012; 59(2):137-41. PubMed ID: 22248270
[TBL] [Abstract][Full Text] [Related]
3. The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas.
Setsu N; Yamamoto H; Kohashi K; Endo M; Matsuda S; Yokoyama R; Nishiyama K; Iwamoto Y; Dobashi Y; Oda Y
Cancer; 2012 Mar; 118(6):1637-48. PubMed ID: 21837670
[TBL] [Abstract][Full Text] [Related]
4. Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.
Okumura Y; Kohashi K; Tanaka Y; Kato M; Maehara Y; Ogawa Y; Oda Y
Virchows Arch; 2020 Jun; 476(6):881-890. PubMed ID: 31927624
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of NQO1 expression in intrahepatic cholangiocarcinoma.
Wakai T; Shirai Y; Sakata J; Matsuda Y; Korita PV; Takamura M; Ajioka Y; Hatakeyama K
Int J Clin Exp Pathol; 2011 Apr; 4(4):363-70. PubMed ID: 21577322
[TBL] [Abstract][Full Text] [Related]
6. High expression of matrix metalloproteinase-9 indicates poor prognosis in human hilar cholangiocarcinoma.
Sun Q; Zhao C; Xia L; He Z; Lu Z; Liu C; Jia M; Wang J; Niu J
Int J Clin Exp Pathol; 2014; 7(9):6157-64. PubMed ID: 25337264
[TBL] [Abstract][Full Text] [Related]
7. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
8. Expression and alterations of the PTEN / AKT / mTOR pathway in ameloblastomas.
Scheper MA; Chaisuparat R; Nikitakis NG; Sauk JJ
Oral Dis; 2008 Sep; 14(6):561-8. PubMed ID: 18826385
[TBL] [Abstract][Full Text] [Related]
9. Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression.
Lu D; Han C; Wu T
Gastroenterology; 2011 Jun; 140(7):2084-94. PubMed ID: 21354147
[TBL] [Abstract][Full Text] [Related]
10. The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma.
Wu N; Du Z; Zhu Y; Song Y; Pang L; Chen Z
Technol Cancer Res Treat; 2018 Jan; 17():1533033818758772. PubMed ID: 29463194
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.
Xu G; Zhang W; Bertram P; Zheng XF; McLeod H
Int J Oncol; 2004 Apr; 24(4):893-900. PubMed ID: 15010827
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma.
Shin E; Choi CM; Kim HR; Jang SJ; Park YS
Lung Cancer; 2015 Jul; 89(1):13-8. PubMed ID: 25936472
[TBL] [Abstract][Full Text] [Related]
13. The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma.
Chung JY; Hong SM; Choi BY; Cho H; Yu E; Hewitt SM
Clin Cancer Res; 2009 Jan; 15(2):660-7. PubMed ID: 19147772
[TBL] [Abstract][Full Text] [Related]
14. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
[TBL] [Abstract][Full Text] [Related]
15. EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors.
Dobashi Y; Suzuki S; Sato E; Hamada Y; Yanagawa T; Ooi A
Mod Pathol; 2009 Oct; 22(10):1328-40. PubMed ID: 19648884
[TBL] [Abstract][Full Text] [Related]
16. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS
Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589
[TBL] [Abstract][Full Text] [Related]
17. CA9 overexpression is an independent favorable prognostic marker in intrahepatic cholangiocarcinoma.
Gu M
Int J Clin Exp Pathol; 2015; 8(1):862-6. PubMed ID: 25755787
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
[TBL] [Abstract][Full Text] [Related]
19. High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral resection.
Chaux A; Compérat E; Varinot J; Hicks J; Lecksell K; Solus J; Netto GJ
Urology; 2013 Jan; 81(1):116-22. PubMed ID: 23273076
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA
Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
